Overview: FISH Multiple Myeloma CD138 Panel
Introduction: The FISH Multiple Myeloma CD138 Panel is a diagnostic tool designed to screen for multiple myeloma chromosomal abnormalities using whole blood or bone marrow samples. In India, multiple myeloma is the second most common hematologic malignancy (~15,000â€"20,000 new cases/year), with FISH on CD138+ plasma cells detecting high-risk abnormalities (del(17p), t(4;14), t(14;16), gain(1q), del(1p)) in ~50-70 percent of cases, guiding prognosis and therapy (bortezomib, daratumumab, lenalidomide). High morbidity from under-testing in rural/low-SES patients presenting with anemia, bone pain, renal failure, limited FISH labs, delayed risk-adapted treatment leading to early relapse or mortality. Per hematology practices aligned with ICMR and Indian Myeloma Academy guidelines, the test employs fluorescence in situ hybridization (FISH) with CD138 enrichment for 6 probes over 1-2 days with high sensitivity/specificity, valuable for molecular subtyping at diagnosis and relapse. This diagnostic falls under genetic cancer screening and targets multiple myeloma patients, addressing accurate detection to guide intensive therapy or clinical trials. With elevated morbidity due to under-testing, the test supports public health efforts by enabling precise risk stratification and improving survival. Its blood/bone marrow-based approach ensures reliable plasma cell-specific abnormality detection in India's growing oncology centers.
Other Names: FISH MM Pnl.
FDA Status: FDA approved, CLIA certified for cytogenetics/oncology, compliant with 2025 standards.
Historical Milestone: CD138-enriched FISH standard; in India, used in myeloma protocols.
Purpose: The test detects 2 parameters including CD138+ cell abnormalities to guide multiple myeloma genetic assessment, identify high-risk features, inform therapy/prognosis.
Test Parameters: 1. CD138+ Cell Abnormalities (6 Probes), 2. Chromosomal Rearrangements.
Pretest Condition: No fasting required; patients should have confirmed or suspected multiple myeloma.
Specimen: 3 mL whole blood or bone marrow in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for FISH).
Medical History: Patients should provide details on myeloma stage, CRAB symptoms, prior therapy.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undetected high-risk abnormalities including poor prognosis, benefits of profiling, and minimal discomfort from blood/bone marrow draw.
Procedural Considerations: The test involves sample processing using FISH with CD138 enrichment by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided probes/controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or low plasma cell count can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: High-risk abnormalities indicate poor prognosis, necessitating specialist input. Standard-risk may require follow-up.
Specialist Consultation: Hematologists/oncologists should be consulted for management.
Additional Supporting Tests: Karyotype, NGS for confirmation.
Test Limitations: Probe-specific only; comprehensive approach required.
References: Indian Journal of Hematology 2024, Myeloma Studies India 2023.
